약물 스크리닝 시장 규모, 점유율, 동향 분석 리포트 : 제품 유형별, 샘플 유형별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Drug Screening Market Growth & Trends:

The global drug screening market size is estimated to reach USD 11.99 billion by 2030 and is anticipated to expand at a CAGR of 4.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by increasing workplace safety concerns, regulatory compliance, and the requirement for accurate detection of substance abuse, aided by technological advancements in testing methods.

The increase in number of adults in contact with drug and alcohol services in England has increased from 275,896 in 2020 - 2021¬ to 289,215 in 2021 - 2022, representing a 4.8% rise, which signifies a growing prevalence of substance abuse in the country. The rising prevalence of substance abuse further propels the need for effective prevention and treatment strategies, including the expansion of access to evidence-based treatment options and public health campaigns to raise awareness about the risks of drug and alcohol misuse.

Furthermore, the incidence of illegal substance uses amongst Americans aged 12 and older in 2020 was around 37.31 million, and shows a 3.8% year-over-year increase over the years; this rising prevalence serves as a significant driver for the market. This increase highlights the urgent need for comprehensive drug screening programs in workplaces, schools, and healthcare settings to ensure safety, compliance with regulations, and provision of appropriate care and support for individuals struggling with substance abuse.

Furthermore, initiatives by market players such as new product launches, mergers, acquisitions, and others contribute to market growth. For instance, in February 2024, Mobile Health, the leading drug testing provider in NYC, launched rapid drug testing for employers, ensuring results in an hour or less. With a focus on urine-based testing for accuracy and versatility, this innovation advances the hiring procedure, revolutionizing talent acquisition in NYC. In addition, in December 2023, the FDA's approval of the AvertD test, which assesses an individual's risk of developing opioid use disorder through genetic markers, marks a significant innovation in the fight against the opioid crisis. This test, developed by AutoGenomics, Inc., is designed to be used before a patient is first exposed to oral opioid pain medications, particularly in patients scheduled for surgical procedures. The test is intended to help patients and healthcare providers make informed decisions about opioid use, potentially reducing the risk of addiction and misuse.

Drug Screening Market Report Highlights:

• Consumables held the largest revenue share of 34.5% in 2024, attributed to their essential role in rapid, accurate, and on-site testing. Furthermore, frequent product launches and the need for efficient substance detection across workplaces and healthcare settings also fuel this segment's growth
• Services and others are expected to grow at a CAGR of 4.1% over the forecast period, owing to the increasing need for specialized drug screening services, including laboratory analysis and support for compliance with regulatory standards.
• Urine samples dominated the market with the largest revenue share of 41.3% in 2024, primarily driven by their noninvasive, simple, and convenient collection process, which makes them suitable for both workplace and clinical settings.
• Oral fluid samples are expected to grow at a significant CAGR over the forecast period, driven by their ease of collection, minimal privacy concerns, and lower risk of sample adulteration.
• In 2024, drug treatment led the market and accounted for the largest revenue share. Hospitals are expected to grow at the fastest CAGR of 5.2% from 2025 to 2030.
• North America dominated the global drug screening market with the largest revenue share in 2024, driven by rising substance abuse rates, stringent workplace safety regulations, and increasing government initiatives aimed at controlling drug-related issues.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Type
  • 1.2.2. Sample Type
  • 1.2.3. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product Type Outlook
  • 2.2.2. Sample Type Outlook
  • 2.2.3. End Use Outlook
  • 2.2.4. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Global Drug Screening Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Global Drug Screening Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. Global Drug Screening Market: Product Type Business Analysis

• 4.1. Product Type Segment Dashboard
• 4.2. Drug Screening Market: Product Type Movement Analysis
• 4.3. Global Drug Screening Market Size & Trend Analysis, By Product Type, 2018 to 2030 (USD Million)
• 4.4. Instruments
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Immunoassays Analyzers
    • 4.4.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Chromatography Instruments
    • 4.4.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Breath Analyzer
    • 4.4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 4.4.4.2. Fuel Cell Breath Analyzer
      • 4.4.4.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 4.4.4.3. Semi-Conductor Breath Analyzer
      • 4.4.4.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 4.4.4.4. Others Breath Analyzer
      • 4.4.4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.5. Rapid Testing Devices
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Urine Testing Devices
    • 4.5.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 4.5.2.2. Drug Testing Cups
      • 4.5.2.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 4.5.2.3. Dip Cards
      • 4.5.2.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 4.5.2.4. Drug Testing Cassettes
      • 4.5.2.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Oral Fluid Testing Devices
  • 4.5.4. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.6. Consumables
  • 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.6.2. Assay Kits
    • 4.6.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.6.3. Sample Collection Devices
    • 4.6.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.6.4. Calibrators & Controls
    • 4.6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.6.5. Other Consumables
    • 4.6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.7. Services & Others
  • 4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Global Drug Screening Market: Sample Type Business Analysis

• 5.1. Sample Type Segment Dashboard
• 5.2. Drug Screening Market: Sample Type Movement Analysis
• 5.3. Global Drug Screening Market Size & Trend Analysis, By Sample Type, 2018 to 2030 (USD Million)
• 5.4. Urine Samples
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. Breath Samples
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.6. Oral Fluid Samples
  • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.7. Hair Samples
  • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.8. Other Samples
  • 5.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Global Drug Screening Market: End Use Business Analysis

• 6.1. End Use Segment Dashboard
• 6.2. Drug Screening Market: End Use Movement Analysis
• 6.3. Global Drug Screening Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.5. Criminal Justice & Law Enforcement Agencies
  • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.6. Workplaces
  • 6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.7. Drug Treatment Centers
  • 6.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.8. Individual Users
  • 6.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.9. Pain Management Centers
  • 6.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.10. Schools & Colleges
  • 6.10.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.11. Others
  • 6.11.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Global Drug Screening Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market Share Analysis, 2024 & 2030
• 7.3. Global Drug Screening Market by Regional: Key Takeaways
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key Country Dynamics
    • 7.4.1.2. Regulatory Framework/ Reimbursement Structure
    • 7.4.1.3. Competitive Scenario
    • 7.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Canada
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework/ Reimbursement Structure
    • 7.4.2.3. Competitive Scenario
    • 7.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Mexico
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework/ Reimbursement Structure
    • 7.4.3.3. Competitive Scenario
    • 7.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Germany
    • 7.5.1.1. Key Country Dynamics
    • 7.5.1.2. Regulatory Framework/ Reimbursement Structure
    • 7.5.1.3. Competitive Scenario
    • 7.5.1.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework/ Reimbursement Structure
    • 7.5.2.3. Competitive Scenario
    • 7.5.2.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5.3. France
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework/ Reimbursement Structure
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Italy
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework/ Reimbursement Structure
    • 7.5.4.3. Competitive Scenario
    • 7.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5.5. Spain
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework/ Reimbursement Structure
    • 7.5.5.3. Competitive Scenario
    • 7.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Denmark
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework/ Reimbursement Structure
    • 7.5.6.3. Competitive Scenario
    • 7.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework/ Reimbursement Structure
    • 7.5.7.3. Competitive Scenario
    • 7.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5.8. Norway
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework/ Reimbursement Structure
    • 7.5.8.3. Competitive Scenario
    • 7.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key Country Dynamics
    • 7.6.1.2. Regulatory Framework/ Reimbursement Structure
    • 7.6.1.3. Competitive Scenario
    • 7.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework/ Reimbursement Structure
    • 7.6.2.3. Competitive Scenario
    • 7.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6.3. India
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework/ Reimbursement Structure
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Australia
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework/ Reimbursement Structure
    • 7.6.4.3. Competitive Scenario
    • 7.6.4.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Thailand
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework/ Reimbursement Structure
    • 7.6.5.3. Competitive Scenario
    • 7.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework/ Reimbursement Structure
    • 7.6.6.3. Competitive Scenario
    • 7.6.6.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key Country Dynamics
    • 7.7.1.2. Regulatory Framework/ Reimbursement Structure
    • 7.7.1.3. Competitive Scenario
    • 7.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Argentina
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework/ Reimbursement Structure
    • 7.7.2.3. Competitive Scenario
    • 7.7.2.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.8. Middle East & Africa
  • 7.8.1. South Africa
    • 7.8.1.1. Key Country Dynamics
    • 7.8.1.2. Regulatory Framework/ Reimbursement Structure
    • 7.8.1.3. Competitive Scenario
    • 7.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework/ Reimbursement Structure
    • 7.8.2.3. Competitive Scenario
    • 7.8.2.4. South Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.8.3. UAE
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework/ Reimbursement Structure
    • 7.8.3.3. Competitive Scenario
    • 7.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.8.4. Kuwait
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework/ Reimbursement Structure
    • 7.8.4.3. Competitive Scenario
    • 7.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key Company Heat Map Analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Abbott
    • 8.4.1.1. Company Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Quest Diagnostics Incorporated
    • 8.4.2.1. Company Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. F. Hoffmann-La Roche Ltd
    • 8.4.3.1. Company Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Thermo Fisher Scientific Inc.
    • 8.4.4.1. Company Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Siemens Healthcare AG
    • 8.4.5.1. Company Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Laboratory Corporation of America Holdings
    • 8.4.6.1. Company Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Alfa Scientific Designs, Inc.
    • 8.4.7.1. Company Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. OraSure Technologies, Inc.
    • 8.4.8.1. Company Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Omega Laboratories, Inc.
    • 8.4.9.1. Company Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Dragerwerk AG & Co. KGaA
    • 8.4.10.1. Company Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives
  • 8.4.11. Bio-Rad Laboratories, Inc.
    • 8.4.11.1. Company Overview
    • 8.4.11.2. Financial Performance
    • 8.4.11.3. Product Benchmarking
    • 8.4.11.4. Strategic Initiatives